| gap-pubmed-20260410- | How does lipofuscin mechanistically increase lysosomal accumulation of tau fibri | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms cause LDLR recycling defects specifically with lipApoE | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do these 17β-E2 protective effects translate to in vivo AD models and human fema | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does Aβ25-35 selectively suppress Wnt3a/β-catenin while increasing GSK-3β in | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does 17β-E2 specifically activate Wnt3a expression upstream of β-catenin sig | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does SKP1A deficiency specifically target dopaminergic neurons over other ce | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do gene-environment interactions modify SKP1A deficiency-induced neurodegene | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link SKP1A deficiency to Lewy body-like inclusion form | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the identified platelet protein candidates (ATP6V0C, AP4B1, RAB2B, etc.) | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive endomembrane system organization upregulation specifically | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the bidirectional causality between AD pathology and epileptogen | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TYROBP regulate the transition from physiological to pathological synap | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms determine the asymmetric sensitivity of inhibitory vs | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do agonistic IR antibodies achieve selective immune suppression without comp | open | 0.57 | 0.00 | 2026-04-10 | 0 | | immunotherapy |
| gap-pubmed-20260410- | What are the specific translational challenges preventing IR agonist therapies f | open | 0.64 | 0.00 | 2026-04-10 | 0 | | immunotherapy |
| gap-pubmed-20260410- | What determines the kinetics of NfL normalization following successful HSCT inte | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do some CALD patients exhibit atypically low NfL despite ongoing myelin dest | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What mechanisms enable NfL to predict AMN-to-CALD conversion before clinical man | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can pharmacodynamic biomarkers be developed to predict CNS pathological chan | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the mechanistic relationship between ASO treatment and sustained neuroin | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why did BIIB078 fail to reduce CNS pathology despite widespread tissue distribut | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can FSH-primed ovarian cortical dopaminergic neurons provide therapeutic benefit | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do FSH-treated cells show lower NSPC marker expression but higher differenti | open | 0.79 | 0.00 | 2026-04-10 | 0 | | stem-cell-biology |
| gap-pubmed-20260410- | What molecular mechanisms underlie FSH's enhancement of dopaminergic differentia | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does peripheral surgical trauma signal to hippocampal microglia to initiate | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does surgical trauma selectively impair context-dependent but not tone-depen | resolved | 0.79 | 0.00 | 2026-04-10 | 0 | | cognitive-neuroscience |
| gap-pubmed-20260410- | What molecular mechanisms drive the metabolic switch from oxidative phosphorylat | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do preclinical gene therapy successes in rodents/primates not consistently t | open | 0.82 | 0.00 | 2026-04-10 | 0 | | translational-neuroscience |
| gap-pubmed-20260410- | What determines optimal AAV serotype selection and delivery routes for different | open | 0.80 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-pubmed-20260410- | How does GULP1 interact with other known APP-interacting proteins in regulating | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which GULP1 enhances APP processing and Aβ ge | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do MIF and cGAS-STING pathways mechanistically regulate mitophagy in hepatic | open | 0.79 | 0.00 | 2026-04-10 | 0 | | mitochondrial-biology |
| gap-pubmed-20260410- | What molecular mechanisms drive the heterogeneity of endothelial cells in hepati | open | 0.77 | 0.00 | 2026-04-10 | 0 | | vascular-biology |
| gap-pubmed-20260410- | How do β-catenin/Wnt and MAPK/ERK pathways interact with TrkB/BDNF signaling in | open | 0.79 | 0.00 | 2026-04-10 | 0 | | cellular-signaling |
| gap-pubmed-20260410- | What mechanisms explain mustard honey's superior antidepressant efficacy compare | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | How do polyphenols in mustard honey cross the blood-brain barrier to activate hi | resolved | 0.84 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-pubmed-20260410- | What are the existing barriers preventing clinical translation of ferroptosis/cu | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms underlying crosstalk between ferropto | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does a lysosomal/endosomal protein form extracellular amyloid fibrils in bra | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does TMEM106B fibrillization initiate neurodegeneration or result from it as a d | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive TMEM106B fibrillization across diverse proteinopathies wit | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does scalp electroacupuncture improve regional cerebral blood flow and vascu | open | 0.76 | 0.00 | 2026-04-10 | 0 | | cerebrovascular-biology |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which electrical stimulation media | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How can the beneficial immunomodulatory pathways of alcohol be therapeutically t | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific mechanisms by which low-moderate alcohol intake provides n | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do circulating oxidative damage markers differentiate between MS subtypes? | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the specific molecular redox mechanisms underlying MS initiation and pr | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does Wnt/β-catenin signaling interact with Hedgehog/Gli1 pathways in FCSC fa | open | 0.56 | 0.00 | 2026-04-10 | 0 | | developmental-biology |
| gap-pubmed-20260410- | What molecular mechanisms explain how β-catenin deletion preserves FCSC pools wh | open | 0.64 | 0.00 | 2026-04-10 | 0 | | cartilage-biology |
| gap-pubmed-20260410- | How does TGFβ signaling mechanistically link BBB dysfunction to disease progress | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |